Physician profile
Erin U Feitz
NPI 1801078308
$36,105.82
in general payments reported to CMS, 2019-2025
45 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,077 · 2022: $2,726 · 2023: $2,778 · 2024: $2,815 · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $9,152 · Travel and Lodging: $2,926 · Education: $399 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,675.00 |
| Food and Beverage | $9,152.45 |
| Travel and Lodging | $2,926.31 |
| Education | $398.63 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $25,226.71 | 2021-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $3,163.65 | 2021-2025 | Tysabri, Vumerity, Avonex |
| Abbvie INC. | $2,199.05 | 2021-2025 | |
| Pfizer INC. | $745.70 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $491.42 | 2021-2025 | |
| Genzyme Corporation | $387.28 | 2021-2025 | |
| Tg Therapeutics, INC. | $359.93 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $355.15 | 2022 | |
| Genentech USA, INC. | $338.93 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Mallinckrodt Hospital Products INC. | $289.59 | 2021-2024 | Acthar |
| Teva Pharmaceuticals USA, INC. | $283.87 | 2021-2025 | Austedo Xr, Austedo Xr |
| Celgene Corporation | $257.79 | 2022-2025 | Zeposia |
| Lilly USA, LLC | $210.47 | 2021-2024 | Kisunla |
| Horizon Therapeutics Plc | $204.05 | 2021-2023 | Uplizna |
| Biohaven Pharmaceuticals, INC. | $188.62 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Feitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.